Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
GlobeNewswire
- 60% response rate observed among 10 evaluable patients
- Favorable safety profile in 26 patients enrolled as..